All Updates

All Updates

icon
Filter
FDA approval
FDA rejects Lykos Therapeutics' MDMA-assisted therapy for PTSD
Psychedelic Medicine
Aug 9, 2024
This week:
Management news
6K Additive awarded project to develop C-103 powder for additive manufacturing
Additive Manufacturing
Sep 27, 2024
Partnerships
WAAM3D partners with Innovative Space Carrier, Cranfield University, and Aichi Sangyo for space transport development
Additive Manufacturing
Sep 19, 2024
Product updates
Akselos introduces software for FPSO monitoring
Digital Twin
Yesterday
Funding
Operant AI raises USD 10 million in Series A funding to boost runtime protection
Next-gen Cybersecurity
Yesterday
Funding
Aembit raises USD 25 million in Series A funding to advance IAM solutions
Identity & Access Management
Yesterday
Product updates
Saviynt launches Intelligence Suite for identity security
Identity & Access Management
Yesterday
Geographic expansion
Partnerships
FarmWise partners with RDO Equipment Co. to expand AI-powered weeding technology for vegetable growers
Smart Farming
Yesterday
Management news
Alberta Food Security Inc. receives USD 5 million order for indoor farming technology
Vertical Farming
Yesterday
Partnerships
AutoStore enhances microfulfilment offering with new grid capabilities and multi-temperature solution
Logistics Tech
Yesterday
Product updates
OpenAI launches o1, a self-fact-checking AI model
Generative AI Applications
Yesterday
Psychedelic Medicine

Psychedelic Medicine

Aug 9, 2024

FDA rejects Lykos Therapeutics' MDMA-assisted therapy for PTSD

FDA approval

  • The FDA has rejected Lykos Therapeutics' application for MDMA-assisted therapy for post-traumatic stress disorder. The FDA requested that Lykos conduct another Phase III trial to study the safety and efficacy of MDMA further.

  • Lykos Therapeutics plans to request a meeting with the FDA to discuss the decision and explore regulatory pathways. The company believes existing data can address many of the FDA's concerns and is committed to finding an expeditious path forward for patients.

  • Analyst QuickTake: The rejection reflects concerns raised during the FDA advisory committee meeting in June 2024 , including issues related to the durability of the treatment's effects, potential expectancy bias from participants with prior MDMA use, and questions about the role of psychotherapy in the treatment.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.